Shots:

• Jnana to receive $40M upfront payment in cash and is eligible to get ~$1B as research funding- preclinical- development- and commercialization milestone along with royalties on sales of the therapies
• The partners will work on the discovery and preclinical development of therapies targeting key regulators of cellular metabolism to treat across immunology and neuroscience while Roche will further develop and commercialize the therapies exclusively
• The collaboration leverages Jnana’s RAPID platform designed to overcome the challenges of directly targeting SLC transporters. The RAPID platform is a cell-based platform that can be used to screen small molecule libraries to identify novel modulators of SLC transporter

  Ref: Businesswire | Image: Roche